PredicineATLAS™
Use
The PredicineATLAS™ assay is designed for comprehensive variant profiling in oncology. It analyzes 600 genes using a CLIA-certified NGS approach to detect single nucleotide variants, indels, rearrangements, copy number gains, gene deletions, and differentiate mono- versus bi-allelic loss of function. Additionally, it assesses key biomarkers, such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), Homologous Recombination Deficiency (HRD), and Tumor Fraction (TF). The assay is used to monitor disease progression and treatment response in cancers, supporting biopharmaceutical partners in identifying suitable molecular profiles for clinical trials and therapeutic interventions.
Special Instructions
Not provided.
Limitations
PredicineATLAS™ is a highly specialized assay focused on variant profiling within 600 selected genes relevant to oncology. While it provides comprehensive coverage of these genes, the test may not detect variants outside this set or identify rare alterations with frequencies below the assay's threshold. Detection sensitivity in plasma is set to a minimum of 0.25% for SNVs and Indels, with a reportable range of 0.05%. For tissue samples, the sensitivity drops to 2.5% for SNVs. The test's clinical applications are mainly in the context of tumor profiling and treatment monitoring, and results are integrated with PredicineSCORE low-pass whole-genome sequencing for enhanced insight.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
6-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4-10 mL
Minimum Volume
4 mL
Container
Two tubes of 10mL blood